Aktiechat - investeringstips

	11/5 17:37 af Helge Larsen/PI-redaktør	This session has ended.
	11/5 17:36 af Jan Van de Winkel	Thank you very much. It has been a pleasure answering your questions. See you next quarter.
	11/5 17:36 af Helge Larsen/PI-redaktør	Jan and David. Thank You for joining us and thank you for the many fullfilling answers to our questions. We wish you a very good presentation at ASCO. We look forward to to seeing you back here on ProInvestor after Q2.
	11/5 17:35 af Jan Van de Winkel	If our board of directors assess a realistic offer for the company is material, we would inform the stakeholders
	11/5 17:34 af MrEbbe	And regarding M&A, when is a offer consider big enough before you let the shareholders know of it?
	11/5 17:34 af Jan Van de Winkel	We believe there is more value for stakeholders in Genmab by remaining independent. Exciting times ahead.
	11/5 17:32 af Jan Van de Winkel	Looking forward...
	11/5 17:32 af investor1989	You stated in Danish media, that the qoutes about a takeover in Dutch Telegraaaf was false. Why hasent Genmab then sought a withdrawal from Telegraaf about the statements?? The article is still not removed, even when it have (your qoute from Børsen TV) misleading qoutes from you?
	11/5 17:32 af Helge Larsen/PI-redaktør	Great. We have 2 questions more left for you.
	11/5 17:32 af Jan Van de Winkel	We have an incredibly exciting pipeline of differentiated drug candidates to invest in and build even greater value for stakeholders in Genmab
	11/5 17:31 af investor1989	You have 3,5 billion DKK in cash and royalty from Darzalex will make genmab cash flow positive at least until patent expiry. So why not use the cash or return some of it - it is not earning interest to Genmab?
	11/5 17:31 af Jan Van de Winkel	Given the unmet medical need in the patient populations for MM and the differentiated nature of daratumumab, we would see the risk as limited.
	11/5 17:29 af bongobob	Do you include the outcome of the American election in you risk analysis when calculating future Darzalez royalties
	11/5 17:29 af Jan Van de Winkel	Daratumumab has been licensed to Janssen, and it should be Janssen that licenses any potential combination partner.
	11/5 17:28 af Solsen	Mr Winkel. Congrats with all the success ! We se a lot of combinations with Darzalex with known drugs as well as not so know molecules. Ex YM-155 - Sepantronium Bromide - which is not approved. Could we se Genmab buy or license a "combination drug" to get a greater part of the MM market
	11/5 17:27 af Jan Van de Winkel	On the investor call last night we mentioned that we potentially could see data from Carina towards the end of the year.
	11/5 17:27 af MUFC Oberanven	When can we expect to see phase II data in NHL / Carina study? Do you expect daratumumab to show equally strong results in NHL as in MM?
	11/5 17:26 af Jan Van de Winkel	The teprotumab studies are run by River Vision and they will update on progress at a future time
	11/5 17:26 af MUFC Oberanven	When do you expect data from the phase II study teprotumumab in graves orbitopathy?
	11/5 17:25 af Jan Van de Winkel	These studies are run by Celimmune so they will update on progress at a future time point
	11/5 17:25 af MUFC Oberanven	What do you expect from AMG714 in Celiac Disease, which is now recruting in 2 phase II studies?
	11/5 17:24 af Jan Van de Winkel	We are currently progressing well in the Phase 1 study with dara subcut and have to do more dosing in this study and then progress to a Phase 3.
	11/5 17:23 af MUFC Oberanven	Yesterday at the q/a you especially highlighted the subcu version of daratumumab. If succesful, how many years are you away from this to hit the market?
	11/5 17:23 af Jan Van de Winkel	The DuoBody collaboration with Novo is progressing well, further updates should come from our partner

	11/5 17:22 af Joakim Von And	Any progress in your work with Novo ,, ? New ideas?
	11/5 17:22 af Jan Van de Winkel	We do not have a factory in Holland, we are moving to a new leased R&D facility in 2017 as we have grown out of our current lab space.
	11/5 17:21 af Joakim Von And	At what time do you plan the new factory in Holland to start production ??
	11/5 17:21 af Jan Van de Winkel	We anticipate patients to enter this study shortly.
	11/5 17:20 af investor1989	Why has JNJ372 not started recruitment yet?
	11/5 17:20 af Jan Van de Winkel	There are multiple interactions between Janssen and other companies, we cant comment further on specific products at this time.
	11/5 17:19 af investor1989	Are Atezolizumab the only Checkpoint Inhibitor Daratumumab will be combined with? or are you also exploring studies with more advanced Keytruda and Opdivo?
	11/5 17:19 af Jan Van de Winkel	The agreement with Roche is not exclusive - and we may well see other combinations with checkpoint blockers to move to clinical evaluation in combi with dara in the near time.
	11/5 17:18 af Sukkeralf	Jan you have mentioned before that you had a favorite checkpoint (PD-1 or PD-L1) combination partner for Darzalex - is atezolizumab (PD-L1) the best choice and why ?
	11/5 17:17 af Jan Van de Winkel	We anticipated that patients will be dosed in this trial imminently.
	11/5 17:16 af Jan Van de Winkel	We are progressing several HexaBody programs within Genmab -the most advanced being HexaBody DR5/DR5 which is firmly slotted to move to the clinic in 2017.
	11/5 17:16 af Sukkeralf	When did the clinical trial with JNJ-61186372 start recruting patients in South Korea (on clinical trials it still says "This study is not yet open for participant recruitment" updated in may ? Is everything progressing as expected and will there only be open locations in South Korea ?
	11/5 17:16 af Jan Van de Winkel	Gilead is in charge of the Zydelig development programs so we have no further information on this at present.
	11/5 17:15 af Stroka	Could you give a general update on the Hexabody development.
	11/5 17:15 af Jan Van de Winkel	We expect further data from the dara POM dex combination study to become public this year.
	11/5 17:15 af Sukkeralf	EMA has started a review of the cancer medicine Zydelig (idelalisib) because an increased rate of serious adverse events (including deaths) has been seen - what influence does it have on the approval process of Ofatumumab+Idelalisib in CLL ?
	11/5 17:14 af Jan Van de Winkel	We expect to see large phase 3 trials to start in the second half
	11/5 17:14 af Sukkeralf	When will we see the Dara-Pom-Dex phase I data published in a journal - and will companion listing give access to 3 line MM (or 4 line as Dara mono) ?
	11/5 17:13 af Jan Van de Winkel	The main focus for Novartis will be in the rapid development of sub cut ofatumumab in MS.
	11/5 17:13 af Sukkeralf	Still no plans for combining Ofatumumab with some of Novartis´ small molecules (BLC-2) with Venetoclax´ recent success in mind?
	11/5 17:12 af Jan Van de Winkel	Janssen is very much on top of the rollout of dara in other territorities. But currently prioritize expansion in the US and in Europe.
	11/5 17:11 af MrEbbe	So far Dara is approved in US, we are waiting for approval from EMA, what is status for the rest of the world regarding an approval of Dara?
	11/5 17:11 af Jan Van de Winkel	At this moment there are no firm plans outside of cancer.
	11/5 17:10 af Sukkeralf	With Janssen/Roche starting clinical trials with Daratumumab in solid tumors are there any chance down the road to see Daratumumab tested as an anti-inflammatory drug ?
	11/5 17:10 af Jan Van de Winkel	....and we continue to be encouraged with the progress in this program.
	11/5 17:10 af Jan Van de Winkel	We still anticipate data for tisotumab vedotin at the end of the year. We are actively recruiting cancer patients in two different trials.....